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Introduction
Allogeneic HSCT is an established therapy for high-risk malignancies such as relapsed leukemia 
and lymphomas, but also for various severe non-malignant diseases. GvHD is a complication of 
hematopoietic stem cell transplantation, with donor immune cells forming responses against host 
antigens, resulting in an immunological rejection of the recipient's tissues. The reaction of donor-
derived immune cells against the recipient's malignant cells describes the graft-versus-tumor or 
-leukaemia (GvL) effect [1] and composes the curative potential of HSCT. Responses against host 
antigens and immunological rejection of the recipient’s tissues describe Graft-versus-host disease 
(GvHD). Two distinct forms of GvHD can be differentiated. Initially, acute GvHD had been defined 
as occurring within the first 100 days, chronic GvHD (cGvHD) after 100 days post-HSCT. With a 
deeper knowledge of the pathogenesis of both acute and chronic GvHD though, and with a better 
understanding of the differences on cellular and clinical levels, the definition has been extended, as 
pathogenesis seems to be different. Incidence of cGvHD may continuously follow aGvHD, occur 
after resolved aGvHD or develop de novo. Various complications can arise from the disease and its 
management still constitutes a big challenge.
Pediatric patients with cGvHD show significantly lower physical functioning than HSCT 
recipients without cGvHD [2], impairment of growth and loss of quality of life. Even if cGvHD 
is known to increase GVL effects, this benefit is outweighed by the increased mortality associated 
with the disease [3,4]. Consequently, the primary goal of post-transplantation therapy is to prevent 
GvHD while enhancing desired GvL effects, thus increasing survival and decreasing disease-relapse. 
Still today, in spite of more than 50 years of experience with HSCT and about 25,000 allogeneic 
HSCTs each year, [5] cGvHD is, after disease-relapse, the most important reason for post-transplant 
mortality [6]. Up to 70% of adult patients develop cGvHD [1], while the incidence in children is lower 
(20-50%), whereas rates have increased since the use of peripheral blood stem cells [7] and donors 
unrelated to the patients [6]. Known risk factors for the development of cGvHD include previous 
aGvHD, stem cell source (PBSC), increasing age of host, CMV-status, TBI and sex-mismatch [6]. 
However, the concrete mechanisms of the development of cGvHD  are still not entirely known. 
While pathogenesis of aGvHD has been studied extensively and seems to be predominantly T cell-
mediated, in recent studies the significance of B cells in cGvHD pathogenesis has been in focus 
[8]. Hypotheses exist, that cGvHD is a mainly Th2-mediated disease with autoimmune features 
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Abstract
B cells and DCs are suspected to play an important role in the pathogenesis of cGvHD, which is a 
serious complication of HSCT with high morbidity. It is characterized by immune responses of donor 
immune cells against recipient-derived antigens. Pathogenesis is not yet fully understood, however 
reconstitution of B cells after HSCT has similarities to physiologic ontogeny. Immunophenotyping 
and co-cultivation-experiments of B cells and DCs from pediatric patients with cGvHD as well as 
healthy donors were conducted. Significant differences between patients and healthy donors were 
observed with increased memory, transitional, CD69+ and CD86+ phenotype and lower levels 
of naïve B cells due to apoptosis. Co-cultivation revealed this to be primarily B cell-dependent 
without major effects of and with DCs. There was a decreased CD11c- phenotype in patients and 
less apoptosis of DCs. Our data suggest a disturbed homeostasis in B cells with increased memory 
phenotype in patients, whereas DCs could not influence these differences, therefore DCs are not 
imposing as promising targets. B cell-dependent approaches should be further investigated.
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[9]. The possible essential steps of its pathogenesis could be triggered 
by damage to the thymus following conditioning prior to HSCT or, 
more significantly, aGvHD. Thus, a decrease in negative selection 
of CD4+ T cells may occur, leading to a deviated immune response 
with increased production of IL-4, IL-5 and IL-11, being part of 
the Th2 cytokine pattern. Tissue fibroblasts can be stimulated both 
directly by Th2-released IL-2, IL-10 and TGFβ1, and indirectly via 
activation of macrophages, which produce PDGF and TGFβ1. This 
process can be enhanced by low Treg levels resulting in further 
deviation of the immune system towards Th2 and Th17 response 
[10]. Th17 cells, a CD4+ T cell subset expressing the IL-23-receptor 
[11], can act as B cell helpers and have been shown to increase the 
formation of germinal centres as well as promoting proliferation and 
activation of B cells with their signature cytokines IL-17, IL-21 and 
IL-22 [12]. This dysregulation of B cell homeostasis can, as well as 
high levels of BAFF, result in B cell autoreactivity [10]. In summation, 
all these steps contribute to systemic effects similar to autoimmune 
diseases affecting multiple organs as skin, nails, mouth, eyes, muscles, 
gastrointestinal tract, liver, lungs, kidneys, heart and bone marrow 
[13-16]. However, an improvement of therapy opportunities is 
desperately needed, as standard therapy consisting of glucocorticoids 
with or without tacrolimus or ciclosporin [1], has many side effects-
especially in pediatric patients [6] and we are still lacking specific 
therapies. Several biomarkers have been introduced and proposed 
for the identification of patients at risk of cGvHD, including Tregs, B 
cells, BAFF, IL-10 [17], as well as development of HY antibodies [18].
While various ways of interaction between DCs and T cells not 
only via antigen presentation are known [19], their influence on B 
cells has just lately become the focus of investigation. Indeed, many of 
the aforementioned mechanisms directly involved in the pathogenesis 
of autoimmunity are complemented or redundantly synergize 
with effects of DCs and B cells on each other. In response to TLR 
stimulation or BCR ligation, pDCs can enhance auto reactive B cell 
proliferation and production of anti-snRNP auto antibodies as well as 
B cell survival [20]. Furthermore, dendritic cells have been shown to 
be the most important APCs. In mouse models anti-CD40 activated 
B cells were unable to fully prime CD4+ T cells in vivo without DCs 
expressing the correct restriction element MHC II I-E [21]. This would 
rather implicate an auxiliary role of B cells in optimizing CD4+ T cell 
priming. Therefore only concerted presentation of antigens by both 
dendritic and B cells leads to an optimal and effective CD4+ T cell-
immunity in-vivo [21]. Additionally, pDCs can induce differentiation 
of CD40-activated B cells into antibody-producing plasma cells via 
sequential secretion of IL-6 and type I IFN [22,23]. This explains, how 
these cytokines, together with BAFF may partially contribute to the 
effects of pDCs on B cell activation in addition to cell-to-cell contact 
[20,24]. Besides these means of communication, a direct involvement 
of the ICAM-1-LFA-1 pathway in the signaling between pDCs and 
auto reactive B cells has been described [20]. As for type I IFN, it is able 
to upregulated CD38 on B cells and enhance secretion of BAFF and 
APRIL by B cells, monocytes and mDCs, confirming its importance 
in the context of cGvHD [25,26]. Follicular DCs are involved in the 
development of somatically mutated and switched memory cells [27]. 
Following activation via TLR7/8-L and, less pronounced, via TLR9, 
pDCs have been shown to be able to induce upregulation of BLIMP1 
and X-box binding protein 1, to increase B cellproliferation as well 
as the differentiation into CD27high plasmablasts [28] which indicates 
their involvement in B cellhomeostasis.
The aims of our study were to compare patterns of B cells and 
DCs from patients with cGvHD and healthy donors. Furthermore, 
apoptosis was measured and co-cultivation was used to observe 
possible interactions and evaluate the effects of B cell activation on 
immune cells.
Materials and Methods
We performed immunophenotyping of B cells and DCs from 
7 pediatric patients (Table 1) with cGvHD and 13 healthy donors. 
Mononuclear cells were isolated from peripheral blood via Ficoll, 
followed by positive selection of CD19+ and CD14+ cells via MACS 
(Miltenyi Biotec, Bergisch Gladbach, Germany). B cells were 
cultivated with IL-10 (Sigma, Taufkirchen, Germany), CD14+ cells 
matured and differentiated to fast DCs within 48 hours with GM-
CSF, IL-4, IL-1b, IL-6, TNFα (CellGenix, Freiburg, Germany) and 
PGE2 (Pharmacia Limited, Kent, UK) [29].
Cocultivation
Co-cultivation of B cells and DCs was performed in order to 
determine effects of cell-type and -origin. At day 3 co-cultivation of 
B cells and DCs was initiated based on characterization of the cells, 
namely auto-auto (B cells patient + DCs patient), auto-allo (B cells 
patient + DCs donor), allo-auto (B cells donor + DCs patient) and 
allo-allo (B cells donor + DCs donor).
#1 #2 #3 #4 #5 #6 #7
Sex m m m m m m m
Age (Years) 12 4 7 20 7 15 8
Diagnosis MDS AML ALL ALL AIE AML LCH
Days Since HSCT 332 1074 755 302 2068 484 2784
Status before HSCT SD PD PR CR SD SD PD
HLA Status Ident Ident Ident Ident Haploident Ident Ident
Donor Sibling Unrelated Fremd Sibling Parental Sibling Fremd
Type of HSCT PBSCT PBSCT PBSCT PBSCT PBSCT PBSCT PBSCT
Sex Mismatch No No Yes No Yes Yes Yes
Relapse No Yes No No No No No
aGvHD Yes Yes Yes Yes No No Yes
Localisation >2 >2 Skin Skin, Liver >2 Skin Skin
Table 1:
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B cell activation
Additionally, we investigated B cell activation by further 
dividing our samples into 4 equal parts and adding anti-IgM 
(Jackson Laboratories, Pennsylvania, USA), CpG and Gardiquimod 
(InvivoGen, San Diego, USA) or leaving blank at days 3 and 4 (Figure 
1). Immunophenotypingwas performed at days 1, 3, 4 and 5.
Statistical analysis
All  p-values were two-sided, considered significant below .05 
and determined via independent T-tests. We compared the means 
of relative proportions of cells determined via immunophenotyping. 




No considerable differences between patients and healthy 
donors were observed at days 1 and 3. Not until 96 hours after cell 
culture were we able to measure significantly diverse cell counts. 
An increased transitional, CD69+ and CD86+ (Figure 2) as well as 
decreased mature naïve phenotype was observed at days 4 and 5 in 
patients with cGvHD compared to healthy controls. Higher levels of 
CD34+ memory cells and lower levels of BAFF-R+ naïve cells were 
measured at day 5, coincident with increased apoptosis of naïve and 
non-switched memory B cells (Table 2).
When taking the co-cultivation into consideration we can see 
these observations confirmed. In none of the subsets do we see a 
significant difference in cell counts between patients and auto-allo, 
indicating no effect of DC-origin on B cells. Similarly, we did observe 
significant differences between healthy donors and auto-allo in every 
B cell subset except for BAFF-R+naïve B cells (Table 3).
DCs
We observed a decreased CD11c- phenotype in patients at 
day 5 and less apoptosis in DCs. Other DC subsets did not differ 
significantly (Table 2).
Figure 1: Experiment setting (A) day 1: Isolation of CD19+ and CD14+ mononuclear cells via MACS, adding respective agents for B cell culture und DC-
maturation, FACS day 2: adding agents for DC-differentiation, day 3: cocultivation, adding B cell activation agents and FACS with Apoptosis measurement, day 4: 
repeating B cell activation and FACS, day 5: FACS with Apoptosis measurement and Co-cultivation schematic (B) with 16 well design for co-cultivation.
Figure 2: Comparison of percentages of CD69+ and CD86+ B cells in co-
cultures with 95% confidence interval: a CD69+ B cells b CD86+ B cells, * 
p-value < .05, ** p-value ≤ .001
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Co-cultivation reveals significant differences only between 
healthy donors and auto-allo (Table 3).
Discussion
Interestingly, reconstitution of B cells after HSCT has similarities 
to physiologic ontogeny [30] yet, the B cell compartment in patients 
after HSCT differs from that of healthy adults [31]. Compared to 
other immune cells, reconstitution of B cells is the slowest, with 
reduced levels in up to 31% of pediatric patients even 12 months after 
transplant [32]. Firstly, levels of memory followed by transitional and 
naïve B cells rise [33,34]. Recovery of B lymphocytes in children has 
been observed to be significantly faster after unrelated transplant of 
cord blood than BMT, although without impact on overall survival 
[35]. PBSCT results in higher counts of B lymphocytes in the 
peripheral blood early after engraftment compared to BMT, whereas 
there is no difference later [36]. Peripheral blood B cells don't reach 
normal counts until up to one year after HSCT and consist of only 
donor-derived lymphocytes [30,37]. GvHD is an important factor 
in delayed reconstitution of lymphocyte pools, and especially B 
cells after HSCT [27,32,38]. Furthermore, development of chronic 
GvHD correlates with delayed recovery of B lymphocytes [32]. 
Concomitantly, high counts of B cell precursors correlate with a 
significantly lower incidence of cGvHD, indicating unaltered B cell 
lymphopoiesis [39]. Increased numbers of transitional [37] and naïve 
B cells [40] are found after HSCT. Early after transplant, the B cell 
CDR3 repertoire is restricted, but after 12 months post-HSCT the 
variability of naïve B lymphocyte pattern isn't significantly different 
from healthy controls, whereas a restricted repertoire of memory B 
cells still exists [41]. Up to 6 months after HSCT, IgH CD3 repertoire 
disparities between memory and naïve B cells have been detected, 
indicating compromised reconstitution of CD27+ memory B 
lymphocytes [37,40,42]. In pediatric patients, CD27- IgMhigh cells have 
been observed to constitute the largest population of B lymphocytes in 
the first 12 months after HSCT, with levels decreasing over time. This 
subset has been further divided into transitional and non-transitional 
cells, which in turn were differentiated via CD45RBMEM55 [31]. In the 
first two years, levels of memory B cell are very low whereas naïve 
B cells are predominant and B lymphocyte reconstitution resembles 
the physiologic development in children [27]. Furthermore, the 
level of CD27+ IgM- memory cells has been found to proportionally 
increase, whereas CD27+ IgMhigh memory B cells would not increase 
and stay lower than compared to a control group [31]. It has been 
proposed, that the occurrence of new B cells after HSCT may serve as 
a predictive determinant of later B cell levels [43].
Bcells and cGvHD
In models for several autoimmune diseases, including rheumatic 
arthritis and JIA,autoreactive B cells, emerging from failure of 
tolerance checkpoints, play an important role [1,44]. Elevated levels 
of TNFα and IL-6, commonly associated with classic autoimmune 
diseases, can also be found in cGvHD patients [11]. Delayed or 
disturbed B cell-reconstitution and elevated plasma B cell–activating 
factor levels are associated with increased numbers of circulating 
CD27+ B cell subsets [45]. Furthermore, this observation is associated 
with significantly higher B cell-protein contents [46], which comprise 
antigen-experienced B cells with a correlating commitment to plasma 
cell differentiation [47]. Indeed did we find higher levels of memory 
B cells in the patient population as compared to healthy donors. In 
addition, cGvHD patients who demonstrate clinical improvement 
and positive response to treatment have robust recovery of the 
peripheral naïve B cell pool [45,48]. This suggests, concomitant with 
an observed increase of IgD+ CD38high CD27- in healthy HSCT patients 
[45], that the return to B cell homeostasis might be critical in the 
prevention of autoimmune cGvHD [49] and indeed, in our patients 
we observed less naïve IgD+ CD27- B cells, as well as increased levels 
of transitional cells. This might be due to delayed and impaired B cell 
reconstitution in cGvHD patients. CD34- CD20+ B cells, known to 
positively correlate, where as CD34+ CD19+ progenitor B cells in the 
Table 2:
Cell Subset
Day 4 Day 5
Mean Median SD p-Value Mean Median SD p-Value
CD34+ Memory
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Table 3:




p-Value Day 4 p-Value Day 5
 




- Auto-Allo 0.54 0.844
- Allo-Auto 0.474 0.23
 
Donors
< Auto-Allo 0.045 0.004
















- Allo-Auto 0.077 0.296
 
Donors
> Auto-Allo 0.046 0.019
















> Allo-Auto 0.027 0.012
 
Donors
< Auto-Allo 0.011 0.092







- Auto-Allo 0.777 0.652

















- Auto-Allo 0.611 0.757
< Allo-Auto 0.007 0.042
 
Donors
> Auto-Allo 0.008 0.025
- Allo-Auto 0.264 0.446
 
 













- Allo-Auto 0.654 0.227
> Auto-Allo 0.136 0.062
















- Allo-Auto 0.639 0.564
 
Donors
> Auto-Allo 0.256 0.005
- Allo-Auto 0.98 0.137
 
 























- Auto-Allo - 0.304
- Allo-Auto - 0.3
 




- Auto-Allo - 0.882
- Allo-Auto - 0.592
 
Donors
- Auto-Allo - 0.738
 - Allo-Auto - 0.863
 




- Auto-Allo - 0.195
- Allo-Auto - 0.817
 
Donors
- Auto-Allo - 0.144
> Allo-Auto - 0
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transplant would correlate inversely with GvHD incidence [50]. In 
patients with cGVHD, less CD24hi CD27+ BcellsandIL-10–producing 
CD24hi CD27+ Bcells have been detected [42]. Nevertheless, after HSCT 
no significant correlation between B cell subsets in the bone marrow 
and cGvHD or survival could be detected [51]. With the knowledge, 
that induction of cGvHD depends on interaction of CD4+ T cells with 
B cells, it surprises, that the absence of B cells in secondary recipients 
didn't prevent cGvHD after CD4+ T cells already had contact with 
B  cells [13]. Auto antibodies found in patients with cGvHD are of 
various types, including ANA, anti-dsDNA, anti-smooth muscle, anti 
mitochondrial and anti cardiolipin antibodies [52,53]. In patients 
with extensive GvHD, auto antibodies specifically targeting PDGFR 
and mediating excessive production of collagen have been identified, 
their levels matching the severity of skin involvement or lung fibrosis 
[16]. The occurrence of auto antibodies could be associated with a 
higher incidence of cGvHD and a lower relapse rate [53]. However, 
even if studies find correlations of antibodies with disease severity 
[54], their occurrence is inconsistent [55]. In addition to the described 
interactions of B cell subsets and cGvHD, we detected significantly 
higher levels of CD69+ and CD80+ B cells in patients as compared 
to healthy donors, indicating higher levels of activation. Activated 
alloreactive and autoreactive B cells are associated with cGvHD [56]. 
With no significant differences in B cell subsets concerning apoptosis, 
our co-cultivation experiments do not support the observations made 
in naïve and non-switched memory B cells.
DCs and cGvHD
A decrease in GvHD severity after depletion of CD11chigh donor 
DCs has been observed [57]. In addition, different manifestations 
seem to be dependent on distinctive APC profiles as, for example, 
expression of CD80/86 in T cells for induction of cutaneous cGvHD, 
which could be mediated by both donor and host APCs, whereas 
gut cGvHD was mainly dependent on donor APCs and required 
both CD80/86 and CD40 signaling [58]. CD83, highly expressed 
on DCs, is suggested to contribute to pathways including activation 
of CD4+ and CD8+ T cells as well as B cell homeostasis [59]. PDCs 
are characterized by a CD11cint B220+ phenotype and are capable 
of producing high amounts of type I IFN as well as exerting potent 
T cell stimulation when matured via CD40 or TLR [25,60,61]. This 
stresses the importance of donor DCs, as 80% of peripheral blood 
DCs are replaced by donor cells within 14 days after transplantation 
in human recipients, reaching more than 95% by day 56 [62]. 
Reconstitution of DCs starts at about 2 to 3 weeks after HSCT, with 
numbers of myeloid DCs normalizing, while pDCs don't reach 
normal levels even in 12 months [27]. No significant association 
between DC chimerism and cGvHD has yet been found [63], but 
there is evidence, that host DCs can present host-derived antigen to 
donor T cells and donor DCs have activating effects on alloreactive 
CD8+ T cells [64]. Nevertheless, a profound depletion of host DCs 
and B cells could not prevent GvHD induction [65]. Donor CD11b- 
CD11c+ pDCs have been observed to enhance Th1, CD4+ and type I 
CD8+ CTL immune polarization of donor T cells as well as promoting 
GVL effects without enhancing GvHD, while CD11b+ CD11c+ cDCs 
would induce Th2 and type II CD8+ CTL immune polarization 
[66]. This complements the observation that adding donor myeloid 
or CD11chigh pDCs to the hematopoietic graft results in increased 
severity of GvHD [67]. Our co-cultivation experiments reveal 
significant differences in CD11c- DCs only between healthy donors 
and auto-allo, indicating a mitigating effect of patient B cells on donor 
DC homeostasis. Experimental depletion of host CD11+ DCs wasn't 
able to prevent the disease [65]. Instead, transplantation of CD11b 
depleted bone marrow hematopoietic grafts leads to increased levels 
of donor spleen-derived CD4+ memory T cells mediating augmented 
GVL effects and IFNγ in the recipient [68]. However, higher counts 
of CD123+ CD4+ DCs in the bone marrow graft have been found 
to be associated with decreased incidence of cGvHD but increased 
relapse in recipients [69]. Lack of CD4+ CD25+ Foxp3+ Tregs can 
induce severe autoimmunity [70]. In the presence of TGFβ and all-
trans retinoic acid, mouse DCs can indeed induce antigen-specific 
and immunosuppressive CD4+ CD25+ Foxp3+ Tregs capable of 
persisting for months and attenuating GvHD [71]. Interestingly, in 
patients with cGvHD, Th17 and CD4+ CD25+ Foxp3+ T cells exhibit 
an inverse proportionality [11]. Levels of Th17 cells in patients with 
active cGvHD are significantly elevated in comparison to healthy 
donors; furthermore, patients with inactive GvHD have very low 
counts of Th17 cells in the peripheral blood, making these cells good 
indicators for disease status [11]. In mouse models, treatment with 
regulatory DCs after allogeneic HSCT can mediate an increase in 
levels of antigen-specific CD4+ CD25+ Foxp3+ T cells and thus prevent 
cutaneous cGvHD in mice by generating alloreactive Tregs from 
donor derived T cells [72]. Furthermore, experimental therapeutic 
extracorporeal photopheresis increased levels of CD4+ CD25+ Foxp3+ 
and modulate cGvHD activity [73]. Yet, the genotype of the donor 
for the (GT)n Polymorphism in the Promoter/Enhancer of Focp3 has 
no correlation with the development of cGvHD [74]. Type I IFN acts 
in autoimmune pathogenesis by negatively affecting differentiation 
of Th2 and Th17 cells [64,75] and inducing antibody responses [26]. 
The immuno modulatory effects of type I IFN include increased 
maturation of DCs and upregulation of expression of MHC I and 
II, as well as enhanced levels of CD80/86, BAFF and APRIL [25]. In 
patients after allogeneic HSCT, CD4+ CD123+ pDC precursors were 
able to produce type I IFN [76] and in mice, pDCs expressing MHCII 
are able to sufficiently prime donor CD4+ T cells to induce GvHD 
[61]. On the other hand, secretion of IFNγ by murine donor T cells 
resulted in increased expression of Indoleamine-2,3-dioxygenase, 
involved in the regulation of gastrointestinal GvHD, [77]in donor 
pDCs, thus altering T cell balance and limiting GvHD without 
inhibition of GVL effects [78]. Furthermore, high levels of IL-15 on 
day +7 post transplant have been observed to correlate significantly 
with a lower risk of cGvHD [79], being involved in autoimmune 
diseases as a modulator of inflammation [80] and enhancing GVL 
effects [81]. We observed no effects of DCs on B-cell-dependent 
pathways, possibly due to less CD11c-regulatory DCs and high levels 
of apoptosis.
Biomarkers
Besides a disturbed B cell-homeostasis [49,51], some previously 
described biomarkers have been associated with an involvement of 
specific organs, such as soluble CD13 and BAFF for hepatic, and anti-
dsDNA antibodies for joint, sclerodermatous and ocular cGvHD 
[52]. In pediatric patients, high levels of IL-2Rα and HGF could be 
significantly associated with GvHD, whereas elevated IL-8 would 
decrease the risk of GvHD [82]. Concentrations of CXCL9 above the 
median have been found to be associated with cGvHD within the first 
three months of diagnosis [83]. CXCL10 and CXCL11 have lately 
been identified as promising diagnostic markers for both aGvHD 
and cGvHD [84]. BAFF also has been suggested as a biomarker for 
cGvHD [49,85], it acts as a survival factor for B cells, as high levels of 
BAFF have been shown to result in increased size and metabolism of 
B cells [46]. Elevated levels of BAFF in patients with cGvHD positively 
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affect numbers of both, pre-germinal center and post-germinal center 
plasmablast- and plasmacell-like B cell subsets [45]. In transgenic 
mice models, over expression of BAFF prevents apoptosis of self-
reactive B cells, leads to an enhancement of anti-dsDNA-specific B 
cell-maturation as well as secretion of antibodies [86] and results in 
autoimmune phenomena [87]. Interestingly, BAFF-receptor deficient 
mice would not develop autoimmunity, indicating a prominent 
role of this factor in disease pathogenesis [88]. Levels of BAFF are 
significantly higher in patients with clinical manifestation of cGvHD 
than in patients without cGvHD [89]. An elevated BAFF/B cell-ratio 
in patients with cGvHD has been observed due to both persistent 
elevation of BAFF concentration and B-lymphopenia, characterized 
by delayed recovery of B cell homeostasis and a selective defect in 
numbers of naive CD27- cells [45]. Despite that, a decrease of soluble 
BAFF levels could predict the clinical response to cGvHD [52]. The 
possibility of BAFF-mediated activation of AKT and ERK pathways 
in patients with cGvHD has been proposed, resulting in decreased B 
cell-apoptosis by lower levels of anti apoptotic Bim via NF-κB pathway 
[46,90]. IL-10 is an important factor in autoimmune pathogenesis 
as observed in experimental autoimmune encephalomyelitis, 
inflammatory bowel disease, collagen-induced arthritis and systemic 
lupus erythematosus [91]. Maturation of DCs under the influence of 
IL-10 induces tolerogenic DCs capable of inducing anergic CD4+ and 
CD8+ cells, inhibiting Th1 and Th2 responses [60]. B cells expressing 
B7 are necessary to mediate expression of IL-10 and Foxp3 by 
CD4+ CD25+ Treg cells in experimental autoimmune encephalitis, 
thus supporting recovery from the disease [92]. In mouse models, 
transferred IL-10-producing B cells were able to reduce cGvHD 
severity due to reconstitution of regulatory B cell subsets and 
have been shown to have a suppressive role in the development of 
sclerodermatous cGvHD [93], as well as mediating the decrease of 
allogeneic donor T cell proliferation and expansion [94]. In patients 
with cGvHD, an impaired production of IL-10 has been observed 
[42]. The detection of allogeneic HY-antibodies 3 months after female 
to male HSCT may predict incidence and severity of cGvHD as well 
as non relapse mortality [95].
Approaches to targeted therapy
Present B cell targeted therapies include anti-CD20, -CD22, -IL-
12/23, -BAFF and -BAFF-receptor-3 antibodies [1,96-98]. A series 
of studies have analyzed the use of rituximab in human cGvHD 
with response rates ranging from 50 to 83% [54]. After treatment 
with rituximab, levels of precursor B cells were significantly higher 
in patients with stable or improved disease showing the correlation 
between clinical response and B cell-homeostasis [99]. On the other 
hand, it has been suggested that rituximab, failing to reduce BAFF 
levels, would induce an even more abnormal BAFF/B cell-ratio and 
support activated B cells [45] and its application as a prophylactic 
agent is still controversially discussed [18,99,100]. Dendritic 
vaccination is a promising approach to induce direct tumor-targeted 
immune responses after HSCT in order to enhance GVL effects. 
Ideally, immune responses against the malignant cells mediated 
by antigen-specific DCs would not have effects on cGvHD [101]. 
However, GvHD negatively affects the desired reactions to vaccines 
[102]. Nonetheless, the setting of HSCT is ideal for application of 
DCs, because, as mentioned earlier, donor DCs tend to fully replace 
host DCs after transplantation [62]. There are several approaches 
to dendritic vaccination against neoplasms, including generation of 
DCs ex vivo by culturing progenitor cells with specific cytokines and 
infusion of these DCs in patients, tumor-associated antigens aimed at 
DCs, and DC-derived exosomes [19]. Disturbed B cell-homeostasis 
and increased autoreactive B cells–critical in the development of 
cGvHD [103] are mediated, amongst others, by type I IFN-producing 
DCs and increased BAFF levels. Both could be influenced by in-vitro 
stimulated pDCs. Further innovative approaches in GvHD therapy 
include tyrosine kinase inhibitors like Imatinibvia Inhibition of 
c-Abl activity possibly blocking autoreactive B cell responses [104] 
and Ibrutinib, an inhibitor of both Bruton’s Tyrosine Kinase and 
IL-2 Inducible T-cell Kinase, enzymes upstream of BCR and TCR 
signaling pathways, having shown promising results in acting as a 
prophylactic agent in murine cGvHD models [105].
Conclusions and Perspectives
Summarizing these observations, an impaired reconstitution of 
the immune cell homeostasis, in particular B cells, seems to be the 
basis of cGvHD pathogenesis, characterized by an increased memory, 
transitional, CD69+ and CD86+ phenotype and lower levels of naïve 
B cells due to Apoptosis.However, despite extensive investigations, 
there is little evidence that findings have facilitated a cohesive 
understanding, have translated into clinically useful tools, or have 
induced new therapeutic strategies. Validated markers for the risk of 
cGvHD development may permit avoidance of donors prone to cause 
cGvHD, alteration of transplant or therapeutic approaches to mitigate 
these risks. Useful and validated biologic markers associated with 
treatment-response and prognosis might positively influence current 
clinical practice and augment the range of therapeutic intervention. 
An advanced understanding of genetic polymorphisms in several 
cytokines, donor-recipient HLA-matching, MHC haplotypes and 
minor histocompatibility mismatch [106] may help to understand 
pathophysiological development of cGvHD [107,108]. As various 
interactions between B cells and DCs exist, DC-mediated priming 
of B cells or dendritic vaccinations seem to imply new therapeutic 
possibilities, even if our results dispute a role of DCs in altered B cell 
homeostasis in cGvHD patients. A priority area for future research 
lies in well-characterized clinical populations in order to obtain 
adequate power for studies in this field. Translation of experimental 
data into a clinical setting might provide useful tools for assessing 
risk for cGvHD and response, and may identify novel therapeutic 
strategies to reduce morbidity and improve prognosis.
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